Certain GSK antibiotic brands are up for sale — report

On Monday, Bloomberg indicated the British drugmaker is working with financial advisers to potentially divest its $200 million-a-year cephalosporin antibiotic business, including the Zinnat and Fortum brands, and the portfolio could fetch several hundred million US dollars, citing people familiar with the matter.